natgillin/translations-raw huggingface dataset:
Bupropion (a medicine used to treat depression or to help you stop smoking): your doctor may need to change your dose of bupropion.
Bupropion (lijek za liječenje depresije ili za pomoć pri prestanku pušenja): liječnik će Vam možda trebati promijeniti dozu bupropiona.
Bupropion (CYP2B6 substrate)
Bupropion (supstrat za CYP2B6)
Bupropion and its metabolites competitively inhibit the OCT2 in the basolateral membrane of the renal tubule responsible for creatinine secretion, in a manner similar to the OCT2 substrate cimetidine.
Bupropion i njegovi metaboliti kompetitivno inhibiraju OCT2 u bazolateralnoj membrani bubrežnih tubula odgovornih za lučenje kreatinina, na način sličan OCT2 supstratu cimetidinu.
Bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the CYP2B6 isozyme.
Bupropion se metabolizira u svoj glavni aktivni metabolit hidroksibupropion prvenstveno preko CYP2B6 izoenzima.
Bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the cytochrome P450 CYP2B6; thus, the potential exists for interaction when administered with medicinal products that induce or inhibit CYP2B6.
Bupropion se metabolizira u svoj glavni aktivni metabolit hidroksibupropion prvenstveno putem citokroma P450 CYP2B6; stoga, postoji potencijal za interakcije prilikom primjene s lijekovima koji induciraju ili inhibiraju CYP2B6.
bupropion, a medicine used to help you stop smoking;
bupropion, koji se koristi za odvikavanje od pušenja;
Bupropion, a medicine used to treat depression or to help you stop smoking, as your doctor may need to change your dose of bupropion.
Bupropion, lijek koji se koristi za liječenje depresije ili kao pomoć za prestanak pušenja: liječnik će možda morati promijeniti dozu bupropiona.
bupropion, used for depression,
bupropion, za liječenje depresije.
bupropion, used for depression.
bupropion, za liječenje depresije.
Bupropion/Tenofovir disoproxil fumarate
Bupropion/tenofovirdizoproksil fumarat
Bupropion:
diltiazem:
buproprion (used to treat depression (sadness)) benzatropine (used to treat Parkinson’s disease)
buproprion (koristi se za liječenje depresije (tuge)) benzatropin (koristi se za liječenje Parkinsonove bolesti)
Buproprion and its active metabolite, hydroxybupropion: AUC and Cmax ↓ ~50%
Buproprion i njegov djelatni metabolit hidroksibupropion: AUC and Cmax ↓ ~50
Burgundy
tamnocrven
Burning
Pečenje
Burning and stinging at the injection site
žarenje i probadanje na mjestu injiciranja
Burning and/or Stinging of short duration at the injection site, Fever (38.5°C or higher), Malaise, Papillitis, Peripheral oedema, Swelling, Tenderness, Vesicles at the injection site, Wheal and Flare at the
kratkotrajno pečenje i/ili bockanje na mjestu injekcije, vrućica (38,5 °C ili viša), opća slabost, papilitis, periferni edemi, oticanje, osjetljivost na dodir, vezikule na mjestu injekcije, oticanje i žarenje na mjestu injekcije
Burning and/or stinging of short duration at the injection site; blisters and/or hives at the injection site.
kratkotrajni osjećaj pečenja i/ili bockanja na mjestu injekcije; pojava mjehurića i/ili koprivnjače na mjestu injekcije
Burning feeling at the site of injection.
Osjećaj pečenja na mjestu injiciranja.
burning in stomach and/or oesophagus
žarenje u želucu i/ili jednjaku
Burning or painful sensation in the tongue, inflammation of the digestive tract lining, excessive gas in the stomach or intestine.
Osjećaj pečenja ili boli u jeziku, upala sluznice probavnog sustava, prekomjerna količina plinova u želucu ili crijevima.
Burning or painful sensation on the tongue
Žarenje ili osjećaj boli na jeziku
burning or prickling of the skin
žarenje ili peckanje kože;
burning or tingling sensation of tongue/mouth
osjećaj žarenja ili trnaca po jeziku/u ustima
burning pain when passing urine feeling weak or generally unwell.
žareću bol pri mokrenju slabost ili opće loše osjećanje
burning sensation
osjećaj žarenja
Burning sensation in the eye
Osjećaj pečenja u očima
burning sensation of skin
osjećaj žarenja na koži
burning sensation when passing urine
osjećaj pečenja pri mokrenju
burning sensation when passing water (urinating) pain in your back or side.
osjećaj pečenja kod mokrenja bol u leđima ili slabinama
burning sensation when passing water (urinating) pain in your back or side.
osjećaj žarenja kod mokrenja bol u leđima ili slabinama.
burning sensation)
osjećaj peckanja)
burning sensation)
osjećaj žarenja)
Burning sensation, headache, neuralgia (intense, typically intermittent pain along the course of a nerve), tremor (an involuntary quivering movement)
Osjećaj peckanja, glavobolja, neuralgija (intenzivna, obično povremena bol duž živca), tremor (nevoljni podrhtavajući pokreti)
burning sensation, partial loss of sensitivity, feeling of “pins and needles” or numbness
žarenje, djelomičan gubitak osjetljivosti, trnci i žmarci ili utrnulost
burning sensation, unpleasant, increased or loss of sense of touch and other non-severe neurological troubles
osjećaj pečenja, neugodan, pojačan osjećaj dodira ili njegov gubitak i druge neurološke poteškoće koje nisu teške
Burning sensation;
Osjećaj žarenja;
burning when passing water diarrhoea.
žarenje pri mokrenju proljev.
Burning, itching, redness and warmth at infusion site, redness at injection site
pečenje, svrbež, crvenilo i toplina na mjestu infuzije, crvenilo na mjestu injekcije
burning, pricking/tingling sensation or diminished sensitivity to sensation
pečenje, osjećaj bockanja ili trnaca ili smanjena osjetljivost na podražaj
burning, prickling, itching or tingling skin sensation
osjećaj peckanja, bockanja, svrbeži ili trnaca
burning, prickling, numbness or tingling sensation of skin
žarenje, trnci, utrnutost ili osjećaj trnaca po koži
Burns
Opekotine.
Burns second degree, accidental exposure (including eye pain, eye and throat irritation and cough)
opekotine drugog stupnja, nehotično izlaganje (uključujući bol u oku, nadraženost očiju i grla te kašalj)
burping
podrigivanje
burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind
podrigivanje, mučnina, povraćanje, žgaravica, bol u trbuhu, suha usta, vjetrovi
burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,
podrigivanje, mučnina, povraćanje, žgaravica, bol u trbuhu, suha usta, vjetrovi
burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,
podrigivanje, mučnina, povraćanje, žgaravica, bol u trbuhu, suha usta, vjetrovi,
burping, stomach ache, changes in your stools such as being oily, urgent need for bowel movements, painful bowel movements
podrigivanje, bol u želucu, promjene stolice poput uljaste stolice, potreba za hitnim pražnjenjem crijeva, bolno pražnjenje crijeva
Busilvex 6 mg/ml concentrate for solution for infusion busulfan
Busilvex 6 mg/ml koncentrat za otopinu za infuziju busulfan
Busilvex 6 mg/ml concentrate for solution for infusion. busulfan.
Busilvex 6 mg/ml koncentrat za otopinu za infuziju busulfan
Busilvex 6 mg/ml sterile concentrate IV
Busilvex 6 mg/ml sterilni koncentrat i.v.
Busilvex consists of a concentrate for solution for infusion and is supplied in colourless glass vials, each vial containing 60 mg of busulfan.
Busilvex se sastoji od koncentrata za otopinu za infuziju i isporučuje se u bezbojnim staklenim bočicama, svaka bočica sadrži 60 mg busulfana.
Busilvex in combination with cyclophosphamide or melphalan In adults
Busilvex u kombinaciji s ciklofosfamidom i melfalanom U odraslih
Busilvex in combination with fludarabine (FB) In adults
Busilvex u kombinaciji s fludarabinom (FB) U odraslih
Busilvex is used in adults and children as part of a ‘conditioning’ (preparative) treatment before transplantation of haematopoietic progenitor cells (the cells that make blood cells).
Busilvex je indiciran u odraslih i djece kao dio terapije kondicioniranja (pripreme) prije presađivanja hematopoetskih progenitorskih stanica (krvotvornih stanica).
Busilvex must be diluted prior to use with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Prije upotrebe, Busilvex je potrebno razrijediti s otopinom natrijeva klorida 9 mg/ml (0,9%) za injekciju ili otopinom 5%-tne glukoze za injekciju.
Busilvex must be prepared by a healthcare professional using sterile transfer techniques.
Busilvex mora pripremiti zdravstveni djelatnik koristeći se sterilnim tehnikama prijenosa.
Busilvex will be administered at 3.2 mg/kg as a single daily three-hour infusion immediately after fludarabine for 2 or 3 consecutive days.
Busilvex se primjenjuje u dozi od 3,2 mg/kg kao trosatna infuzija jednom dnevno odmah nakon fludarabina u 2 ili 3 uzastopna dana.
Busilvex will be administered every 6 hours during 4 consecutive days prior to transplant.
Busilvex će se primjenjivati svakih 6 sati tijekom 4 uzastopna dana prije presađivanja.
Busilvex will be administered once daily during 2 or 3 consecutive days prior to transplant.
Busilvex će se primjenjivati jednom dnevno tijekom 2 ili 3 uzastopna dana prije presađivanja.
Buspirone
Za liječenje plućne
buspirone - used to make you calmer
buspiron - koristi se za umirenje
Buspirone Clorazepate Diazepam Estazolam Flurazepam
Klorazepat Diazepam Estazolam Flurazepam
Buspirone Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A and as a result is expected to increase the plasma concentrations of buspirone.
Buspiron Ritonavir doziran kao farmakokinetički pojačivač ili kao antiretrovirusni lijek inhibira CYP3A te se zbog toga može očekivati povećanje koncentracija buspirona u plazmi.
buspirone, clorazepate, diazepam, estazolam, flurazepam, perphenazine, risperidone, thioridazine, zolpidem, medicines used to treat nervous system disorders
buspiron, klorazepat, diazepam, estazolam, flurazepam, perfenazin, risperidon, tioridazin, zolpidem, lijekovi koji se primjenjuju za liječenje poremećaja živčanog sustava
buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem, medicines used to treat nervous system disorders
buspiron, klorazepat, diazepam, estazolam, flurazepam, zolpidem, lijekovi koji se primjenjuju za liječenje poremećaja živčanog sustava
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion
Busulfan Fresenius Kabi 6 mg/ml koncentrat za otopinu za infuziju
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion busulfan
Busulfan Fresenius Kabi 6 mg/ml koncentrat za otopinu za infuziju busulfan
Busulfan Fresenius Kabi consists of a concentrate for solution for infusion and is supplied in colourless glass vials, each vial containing 60 mg of busulfan.
Busulfan Fresenius Kabi se sastoji od koncentrata za otopinu za infuziju i isporučuje se u bezbojnim staklenim bočicama, svaka bočica sadrži 60 mg busulfana.
Busulfan Fresenius Kabi in combination with cyclophosphamide:
Busulfan u kombinaciji s ciklofosfamidom:
Busulfan Fresenius Kabi in combination with fludarabine
Busulfan u kombinaciji s fludarabinom
Busulfan Fresenius Kabi is a ‘generic medicine’.
Busulfan Fresenius Kabi je „generički lijek”.
Busulfan Fresenius Kabi must be diluted prior to use with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Prije upotrebe, lijek Busulfan Fresenius Kabi se mora razrijediti otopinom natrijeva klorida 9 mg/ml (0,9%) za injekciju ili otopinom 5%-tne glukoze za injekciju.
Busulfan Fresenius Kabi will be administered every 6 hours during 4 consecutive days prior to transplant.
Busulfan Fresenius Kabi će se primjenjivati svakih 6 sati tijekom 4 uzastopna dana prije presađivanja.
Busulfan in combination with cyclophosphamide or melphalan In adults
DoziranjeBusulfan u kombinaciji s ciklofosfamidom ili melfalanom U odraslih
Busulfan in combination with fludarabine (FB) In adults
Buslulfan u kombinaciji s fludarabinom (FB) U odraslih
Busulfan in combination with fludarabine (FB) In adults
Busulfan u kombinaciji s fludarabinom (FB) U odraslih
Busulfan is metabolised mainly through conjugation with glutathione (spontaneous and glutathione-S- transferase mediated).
Busulfan se većinom metabolizira konjugacijom s glutationom (spontano i sudjelovanjem glutation-S-transferaze).
Busulfan is used before transplantation to destroy abnormal cells and the patient’s existing blood- making cells.
Busulfan se koristi prije transplantacije za uništavanje nenormalnih stanica i postojećih krvotvornih stanica bolesnika.
Busulfan is used before transplantation to destroy abnormal cells and the patient’s existing haematopoietic progenitor cells.
Busulfan se koristi prije presađivanja za uništavanje abnormalnih stanica i postojećih hematopoetskih progenitorskih stanica bolesnika.
Busulfan will be administered at 3.2 mg/kg as a single daily three-hour infusion immediately after fludarabine for 2 or 3 consecutive days.
Busulfan se primjenjuje u dozi od 3,2 mg/kg kao trosatna infuzija jednom dnevno odmah nakon fludarabina u 2 ili 3 uzastopna dana.
Busulfan will be administered every 6 hours during 4 consecutive days prior to transplant.
Busulfan Fresenius Kabi će se primjenjivati svakih 6 sati tijekom 4 uzastopna dana prije presađivanja.
Busulfan will be administered once daily during 2 or 3 consecutive days prior to transplant.
Busulfan Fresenius Kabi će se primjenjivati jednom dnevno tijekom 2 ili 3 uzastopna dana prije presađivanja.
But if you have osteoporosis, it makes you more likely to break bones, especially in your spine, hips and wrists.
Međutim, ako patite od osteoporoze, veća je vjerojatnost da ćete slomiti kost, bilo u kralježnici, kukovima ili zapešću.
But not breathing out into the inhaler.
Nemojte izdisati u inhalator.
But please note that the matrix should cover 1-2 cm beyond the margins of the wound.
Matrica treba za 1-2 cm prelaziti rubove rane.
But you must be aware that they are potentially serious — so, if you notice any of these symptoms:
Međutim, morate biti svjesni da oni potencijalno mogu biti ozbiljni – stoga, ako uočite neke od ovih simptoma:
Button Capsule chamber
Komora za kapsulu
button is all the
utisnut do kraja.
Butylated hydroxytoluene
Butilhidroksitoluen
Butylated hydroxytoluene (E321)
Butilhidroksitoluen (E321)
Butylated hydroxytoluene Dipropylene glycol methyl ether Isopropyl alcohol
Butil hidroksitoluen Dipropilen glikol metil eter Izopropilni alkohol
butylated methacrylate copolymer crospovidone
kopolimer (butadien/metakrilat) krospovidon
Butylhydroxyanisole (BHA)
Ovojnica kapsule:
Butylhydroxyanisole Isopropylidene glycerol Lactic acid
Butilhidroksianisol Izopropiliden glicerol Mliječna kiselina
Butylhydroxytoluene (0.01 %)
Butilhidroksitoluen (0,01 %)
Butylhydroxytoluene (E321)
Butilhidroksitoluen (E321)
Butylhydroxytoluene (E321) 1 mg/ml.
Butilhidroksitoluen (E321) 1mg/ml.
Butylhydroxytoluene (E321) Sorbic acid (E200)
Butilhidroksitoluen (E321) Sorbična kiselina (E200) Suncokretovo ulje
Butylhydroxytoluene (E321): 1 mg For the full list of excipients, see section 6.1.
Butilhidroksitoluen (E321) 1 mg Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
butylhydroxytoluene (E321; as antioxidant) 0.9 mg sorbic acid (E200; as preservative) 0.7 mg
butilhidroksitoluen (E321; kao antioksidans) 0,9 mg sorbična kiselina (E200; kao konzervans) 0,7 mg.
Butylhydroxytoluene 1 mg/ml (E 321; as antioxidant).
Butil-hidroksitoluen 1mg/ml (E321; kao antioksidans).
buzzing, hissing, whistling, ringing or other persistent noise in the ears
zujanje, šištanje, pištanje, zvonjenje ili neki drugi neprekidni zvukovi u ušima
BV Cyclotron VU De Boelelaan 1081 1081 HV Amsterdam The Netherlands
BV Cyclotron VU De Boelelaan 1081 1081 HV Amsterdam Nizozemska
BV Cyclotron VU, the Netherlands
BV Cyclotron VU, Nizozemska
BW: Body weight, SD: Standard deviation
TT: tjelesna težina; SD: standardna devijacija
By 1 year By 2 years
Do 1. godine
By 1 year By 2 years
Do 1. godine Do 2. godine
By 12 months
Do 12. mjeseca
By 2 years 39%; P < .0001
Do 2. godine 39%; P < 0,0001
By 24 months
Do 24. mjeseca
By 3 years 50%; P < .0001
Do 3. godine 50%; P < 0,0001
by 31 March
31. ožujka
by 31/03/2021
ispitivanja do
by 31/03/2021
Završno izvješće
By 34 days after the initiation of treatment, 17.5 - 20.0% morbidity and 1.5 - 2.3% mortality were observed in the treated groups in comparison to 50.0 - 53.3% morbidity and 2.5 - 4.8% mortality in the untreated groups.
Do 34 dana nakon početka liječenja, zabilježena je morbidnost od 17,5-20,0 % i smrtnost od 1,5-2,3 % u liječenim skupinama u usporedbi s morbidnošću od 50,0-53,3 % i smrtnošću od 2,5-4,8 % u neliječenim skupinama.
By 4 years 56%; P < .0001
Do 4. godine 56%; P < 0,0001
By 4 years By 5 years
Do 4. godine Do 5. godine
By 4Q 2015
2015
By 5 years By 6 years
Do 5. godine Do 6. godine
By 60 months, the incidence of non-skin malignancies was significantly higher in the cohort who continued ciclosporin as compared with the cohort who had ciclosporin withdrawn (8.4% vs.
Do 60 mjeseci, incidencija zloćudnih bolesti (s izuzetkom kožnih) bila je značajno veća u skupini koja je nastavila uzimati ciklosporin, u usporedbi sa skupinom kojoj je ukinut (8,4% nasuprot 3,8%).
By acting as a ligand trap, aflibercept prevents binding of endogenous ligands to their cognate receptors and thereby blocks receptor mediated signaling.
Djelujući kao zamka za ligande, aflibercept sprečava vezanje endogenih liganada za njima srodne receptore i tako blokira signalizaciju posredovanu receptorima.
By activating factor X, NovoSeven is able to give temporary control of the bleeding disorder.
Aktivirajući faktor X, NovoSeven je u mogućnosti uspostaviti privremenu kontrolu poremećaja krvarenja.
By adding approximately 2 grams of skimmed milk powder or 20 ml of liquid skimmed milk per litre of water the virus retains its activity longer.
Dodavanje oko 2 grama obranog mlijeka u prahu ili 20 ml tekućeg obranog mlijeka po litri vode, produžuje djelovanje virusnog cjepiva.
by atazanavir
pojačivač atazanaviru.
By attaching and blocking PCSK9, Praluent prevents the receptors from being broken down inside cells and therefore increases the number of these receptors on the cell surface, where they can attach to LDL-cholesterol and remove it from the bloodstream.
Vezivanjem na enzim PCSK9 i njihovim inhibiranjem Praluent sprječava razgradnju receptora unutar stanica i stoga povećava broj tih receptora na površini stanica, gdje se mogu vezivati na LDL kolesterol i uklanjati ga iz krvotoka.
By attaching and blocking PCSK9, Repatha prevents the receptors from being broken down inside cells and therefore increases the number of these receptors on the cell surface, where they can attach to LDL-cholesterol and remove it from the bloodstream.
Vezivanjem i blokiranjem enzima PCSK9, Repatha sprječava razgradnju receptora unutar stanica i stoga povećava broj tih receptora na površini stanica, gdje se mogu vezivati na LDL kolesterol i uklanjati ga iz krvotoka.
By attaching to and blocking RANKL, denosumab reduces the formation and activity of the osteoclasts.
Vezujući se na i inhibirajući RANKL, denosumab smanjuje stvaranje i djelovanje osteoklasta.
By attaching to CD20 on B- lymphocytes, obinutuzumab makes the B-lymphocytes a target for the body’s immune (defence) system, which kills the B-lymphocytes.
Vezivanjem na protein CD20 na površini B-limfocita obinutuzumab B-limfocite čini ciljem imunosnog (obrambenog) sustava tijela koji uništava B-limfocite.
By attaching to CD20, ofatumumab stimulates the body’s immune system to attack the cancerous cells, helping to control the disease.
Vezivanjem na CD20 ofatumumab stimulira imunološki sustav tijela za napad na stanice raka i tako pomaže u kontroli bolesti.
By attaching to CD38 on the multiple myeloma cells, daratumumab activates the immune system to kill the cancer cells.
Vezivanjem na CD38 na stanicama multiplog mijeloma daratumumab potiče imunosni sustav da ubija stanice raka.
By attaching to HER2, pertuzumab stops HER2 producing signals that cause the cancer cells to grow.
Vezivanjem na HER2, pertuzumab zaustavlja proizvodnju HER2 signala koji uzrokuju rast stanica raka.
By attaching to IgE, omalizumab ‘mops up’ the free IgE circulating in the blood.
Vezanjem na IgE, omalizumab „čisti“ IgE koji slobodno kruži krvlju.
By attaching to IL-6, siltuximab blocks its activity and stops abnormal cell growth, thus reducing the size of the lymph nodes and the symptoms of the disease.
Vezanjem na IL-6, siltuksimab inhibira njegovo djelovanje i zaustavlja abnormalan rast stanica, te smanjuje veličinu limfnih čvorova i simptome bolesti.
By attaching to integrin, natalizumab is thought to stop the leucocytes from going from the blood into the brain.
Smatra se da natalizumab vezivanjem na integrin sprečava prelazak leukocita iz krvi u mozak.
By attaching to interleukin-1 beta, canakinumab blocks its activity, helping to reduce inflammation thereby relieving the symptoms of the diseases.
Vezivanjem na interleukin-1 beta kanakinumab inhibira njegovo djelovanje te pomaže pri smanjenju upale i ublažavanju simptoma bolesti.
By attaching to interleukin-5, mepolizumab blocks its action and thereby
Vezivanjem na interleukin-5, mepolizumab blokira njegovo djelovanje i tako smanjuje broj eozinofila.
By attaching to it, ramucirumab blocks this action, reducing the blood supply to the tumour and so slowing the growth of the cancer.
Vezivanjem na njih, ramucirumab inhibira njihovo djelovanje, smanjujući opskrbu krvi u tumor i usporavajući rast raka.
By attaching to prostacyclin receptors, Uptravi also widens the blood vessels and so lowers the pressure inside them, improving symptoms of the disease.
Vezivanjem na prostaciklinske receptore lijek Uptravi također širi krvne žile te na taj način smanjuje tlak u njima i poboljšava simptome bolesti.
By attaching to the receptor, nivolumab prevents PD-L1 and PD-L2 from the cancer cells from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells.
Vezivanjem na receptor nivolumab sprječava da PD-L1 i PD-L2 iz stanica raka ugase aktivnost T stanica, čime se povećava mogućnost imunosnog sustava da ubija stanice raka.
By attaching to the receptors that interleukin 1 would normally attach itself to, anakinra blocks the activity of interleukin 1, helping to relieve the symptoms of these diseases.
Vezivanjem na receptore koje bi interleukin 1 normalno vezao na sebe, anakinra inhibira aktivnost interleukina 1 i tako pomaže pri ublažavanju simptoma tih bolesti.
By attaching to VEGF, Avastin stops it having an effect.
Vezivanjem za VEGF, Avastin zaustavlja njegovo djelovanje.
By background NRTI
Prema osnovnom liječenju NRTI-jem
By baseline CD4 count (x 106 cells/L)
Prema početnom broju CD4 (x 106 stanica/l)
By binding the shared p40 subunit of IL-12 and IL-23, ustekinumab may exert its clinical effects in psoriasis, psoriatic arthritis and Crohn’s disease through interruption of the Th1 and Th17 cytokine pathways, which are central to the pathology of these diseases.
Vežući se na zajedničku p40 podjedinicu IL-12 i IL-23, ustekinumab može imati klinički učinak na psorijazu, na psorijatični artritis i na Crohnovu bolest kroz prekid Th1 i Th17 citokinskih putova koji su u središtu patologije ovih bolesti.
By binding to the α4β7 integrin expressed on gut- homing lymphocytes, vedolizumab exerts an immunosuppressive effect on the gut.
Vezanjem na integrin α4β7 izražen na limfocitima u crijevima, vedolizumab iskazuje imunosupresivni učinak na crijeva.
By blocking an enzyme called integrase, elvitegravir stops the virus’s genetic material from integrating into the genetic material of the cells it has infected.
Blokirajući enzim naziva integraza elvitegravir sprječava integraciju genetskog materijala virusa u genetski materijal zaraženih stanica.
By blocking Bcr-Abl kinase, as well as other kinases, Sprycel helps to control the spread of leukaemia cells.
Inhibirajući Bcr-Abl kinazu kao i druge kinaze, Sprycel pomaže u kontroliranju širenja leukemije.
By blocking Btk, ibrutinib decreases survival and migration of B lymphocytes, thereby delaying the progression of the cancer.
Inhibirajući Btk, ibrutinib smanjuje preživljenje i migraciju limfocita B te na taj način odgađa napredovanje raka.
By blocking EGFR, osimertinib helps to reduce the growth and spread of the cancer.
Blokiranjem EGFR-a osimertinib pomaže pri smanjivanju rasta i širenja raka.